Bring Better Medicine to Patients Faster with AI
Stages 1 & 2 are powered by our own BioMedAI platform. Stage 3 is delivered through partners.
AI Target Discovery
Target Intelligence
- Integrate public and proprietary biomedical data
- Leverage proprietary AI models to identify disease-driving targets
- Deliver evidence-backed, ranked target candidates
AI Drug Design
Drug Intelligence
- Modality-optimized design: small molecules, antibodies & peptides
- Hybrid AI: generative AI + physics-based models
- Experience-driven optimization: improve efficacy, safety & developability
Lab & Clinical Validation
Experimental & Clinical Evidence
- Partner-enabled experimental validation
- Drug safety, toxicity & PK/PD assessment
- Clinical evidence and translational validation
Decisions you can trace and trust
CLINAVA™
Predicts how far a target is likely to progress clinically, giving a quantitative basis for choosing which targets to pursue.
GENAVA™
Simulates gene perturbations in silico to validate a target and trace the biological pathways behind each recommendation.
Validate Drug Targets with AI Precision
See how BioMedAI analyzes biomedical data to identify and validate potential drug targets
- Integrated analysis from 40+ biomedical databases
- AI-powered target validation and scoring
- Comprehensive pathway and interaction insights
- Evidence-based target recommendations
Research Digest
AI-curated papers, FDA approvals, clinical compounds, and disclosures from drug discovery's leading sources — scored for relevance by the WeDaita AI agent every week.
News & Blog
Company updates, tutorials, and community posts — all in one place.
No blog posts yet.
AI Drug Discovery, Delivered Monthly
Get curated insights on AI-driven target identification, therapeutic design, and BioMedAI platform updates — directly to your inbox.
No spam. Unsubscribe at any time. We respect your privacy.
Built by People Who Have Lived the Problem
Combining deep domain expertise across AI, biology and chemistry in both academia and industry.
Ecosystem Recognition & Strategic Support
Selected by leading innovation programs supporting AI and life sciences.
Member of NVIDIA’s global startup program accelerating AI innovation — providing access to the NVIDIA AI ecosystem, technical resources, and industry connections.
Qualified for AWS startup support, cloud credits, and infrastructure resources to accelerate scalable AI platform development.
Selected for entrepreneurial support and founder ecosystem access through Harvard Business School’s innovation programs.
Ready to Accelerate Your Drug Discovery?
BioMedAI is live — start with AI Target Discovery and antibody & protein design today.